Investors and Media
Idera Pharmaceuticals is a biopharmaceutical company focused on the acquisition, development and ultimate commercialization of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet needs.
Furthering our commitment to this goal, in September 2022 Idera merged with Aceragen, Inc., a privately-held biotechnology company addressing rare, orphan pulmonology and rheumatology diseases that typically have no treatment. To learn more about Aceragen, visit www.Aceragen.com.
Nov 14, 2022
Sep 28, 2022
Aug 09, 2022
Data Provided by Refinitiv. Minimum 15 minutes delayed.